FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616362023> ?p ?o ?g. }

• W2616362023 endingPage "71932" @default.
• W2616362023 startingPage "71924" @default.
• W2616362023 abstract "// Sergio Rizzo 1, * , Antonina Cangemi 1, * , Antonio Galvano 1, * , Daniele Fanale 1 , Silvio Buscemi 2 , Marcello Ciaccio 3 , Antonio Russo 1 , Sergio Castorina 4, 5, # and Viviana Bazan 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Department of Internal and Specialistic Medicine (DIBIMIS), Laboratory of Clinical Nutrition, University of Palermo, Palermo, Italy 3 Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnology, University of Palermo, U.O.C. Laboratory Medicine, Policlinico University Hospital, Palermo, Italy 4 Fondazione Mediterranea G.B. Morgagni, Catania, Italy 5 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy * These authors contributed equally to this work # These authors contributed equally to this work and co-last authors Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: chemotherapy response, doxorubicin, microRNAs, short term starvation, triple negative breast cancer cells Received: April 13, 2017      Accepted: May 09, 2017      Published: May 19, 2017 ABSTRACT Recent studies showed that dietary approaches restricting food intake can be helpful to hinder tumor progression. To date, the molecular mechanisms are unclear and a key role seems to be exerted by nutrient-related signaling pathways. Since several evidences showed that non-coding small RNAs, including microRNAs, are correlated to cancer progression and antiblastic treatment response, our work aims to study their involvement in a triple negative breast cancer (TNBC) cell line treated with doxorubicin under Short Term Starvation (STS) condition. Human TNBC cell line MDA-MB-231 and healthy breast cell line MCF10A were treated with 1 μM doxorubicin for 24 h under STS condition for 48 h and miRNA expression profiles were analyzed using Taqman ® Low Density Array A human microRNA microfluidic cards. In addition, the expression of specific mRNAs and miRNAs differentially expressed under STS was analyzed using Real-time PCR analyses. MiRNA expression profile analysis in MDA-MB-231 and MCF10A cells treated with doxorubicin under STS for 48 h could explain the molecular mechanisms underlying anticancer effects associated to STS. Among deregulated miRNAs, a subset, including miR-15b, miR-23a, miR-26a, miR-29a, miR-106b, miR-128, miR-149, miR-181a, miR-192, miR-193b, miR-195, miR-324-3p and miR-494, has been shown to be involved in pathways related to drug sensitivity/resistance. The obtained data from our study suggest a potential involvement of some miRNAs in molecular pathways mediating the anticancer effects of STS in doxorubicin-treated breast cancer cells. Preliminary results seem to be encouraging and, in future, could allow the discovery of new potential targets useful for the development of new therapeutic approaches." @default.
• W2616362023 created "2017-05-26" @default.
• W2616362023 creator A5000835780 @default.
• W2616362023 creator A5006712720 @default.
• W2616362023 creator A5033609878 @default.
• W2616362023 creator A5052679600 @default.
• W2616362023 creator A5056636166 @default.
• W2616362023 creator A5070545935 @default.
• W2616362023 creator A5072264918 @default.
• W2616362023 creator A5080996267 @default.
• W2616362023 date "2017-05-19" @default.
• W2616362023 modified "2023-10-01" @default.
• W2616362023 title "Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin" @default.
• W2616362023 cites W1519240165 @default.
• W2616362023 cites W1534849470 @default.
• W2616362023 cites W1792788514 @default.
• W2616362023 cites W1838112979 @default.
• W2616362023 cites W1912921167 @default.
• W2616362023 cites W1918657120 @default.
• W2616362023 cites W1979762673 @default.
• W2616362023 cites W1988105914 @default.
• W2616362023 cites W1992175200 @default.
• W2616362023 cites W2017703699 @default.
• W2616362023 cites W2023809974 @default.
• W2616362023 cites W2051946436 @default.
• W2616362023 cites W2055512270 @default.
• W2616362023 cites W2059746106 @default.
• W2616362023 cites W2063260805 @default.
• W2616362023 cites W2076839554 @default.
• W2616362023 cites W2080094749 @default.
• W2616362023 cites W2084605009 @default.
• W2616362023 cites W2091389812 @default.
• W2616362023 cites W2098964938 @default.
• W2616362023 cites W2105728472 @default.
• W2616362023 cites W2109923675 @default.
• W2616362023 cites W2114993186 @default.
• W2616362023 cites W2126753949 @default.
• W2616362023 cites W2127527009 @default.
• W2616362023 cites W2138474420 @default.
• W2616362023 cites W2150536104 @default.
• W2616362023 cites W2151454553 @default.
• W2616362023 cites W2154493509 @default.
• W2616362023 cites W2159888101 @default.
• W2616362023 cites W2161716852 @default.
• W2616362023 cites W2163006881 @default.
• W2616362023 cites W2214655721 @default.
• W2616362023 cites W2313582062 @default.
• W2616362023 cites W2326250147 @default.
• W2616362023 cites W2340540443 @default.
• W2616362023 cites W2461340879 @default.
• W2616362023 cites W2496209031 @default.
• W2616362023 cites W2515458810 @default.
• W2616362023 cites W2608397573 @default.
• W2616362023 doi "https://doi.org/10.18632/oncotarget.18028" @default.
• W2616362023 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641100" @default.
• W2616362023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069757" @default.
• W2616362023 hasPublicationYear "2017" @default.
• W2616362023 type Work @default.
• W2616362023 sameAs 2616362023 @default.
• W2616362023 citedByCount "26" @default.
• W2616362023 countsByYear W26163620232018 @default.
• W2616362023 countsByYear W26163620232019 @default.
• W2616362023 countsByYear W26163620232020 @default.
• W2616362023 countsByYear W26163620232021 @default.
• W2616362023 countsByYear W26163620232022 @default.
• W2616362023 countsByYear W26163620232023 @default.
• W2616362023 crossrefType "journal-article" @default.
• W2616362023 hasAuthorship W2616362023A5000835780 @default.
• W2616362023 hasAuthorship W2616362023A5006712720 @default.
• W2616362023 hasAuthorship W2616362023A5033609878 @default.
• W2616362023 hasAuthorship W2616362023A5052679600 @default.
• W2616362023 hasAuthorship W2616362023A5056636166 @default.
• W2616362023 hasAuthorship W2616362023A5070545935 @default.
• W2616362023 hasAuthorship W2616362023A5072264918 @default.
• W2616362023 hasAuthorship W2616362023A5080996267 @default.
• W2616362023 hasBestOaLocation W26163620231 @default.
• W2616362023 hasConcept C104317684 @default.
• W2616362023 hasConcept C121608353 @default.
• W2616362023 hasConcept C126322002 @default.
• W2616362023 hasConcept C143998085 @default.
• W2616362023 hasConcept C145059251 @default.
• W2616362023 hasConcept C2776694085 @default.
• W2616362023 hasConcept C2780110267 @default.
• W2616362023 hasConcept C2781303535 @default.
• W2616362023 hasConcept C502942594 @default.
• W2616362023 hasConcept C530470458 @default.
• W2616362023 hasConcept C54355233 @default.
• W2616362023 hasConcept C71924100 @default.
• W2616362023 hasConcept C86803240 @default.
• W2616362023 hasConceptScore W2616362023C104317684 @default.
• W2616362023 hasConceptScore W2616362023C121608353 @default.
• W2616362023 hasConceptScore W2616362023C126322002 @default.
• W2616362023 hasConceptScore W2616362023C143998085 @default.
• W2616362023 hasConceptScore W2616362023C145059251 @default.
• W2616362023 hasConceptScore W2616362023C2776694085 @default.
• W2616362023 hasConceptScore W2616362023C2780110267 @default.
• W2616362023 hasConceptScore W2616362023C2781303535 @default.
• W2616362023 hasConceptScore W2616362023C502942594 @default.

• next